EASME

Vital Beats develops a medical platform for remote care of heart patients with pacemakers. The platform combines participatory design, data science, and machine learning to monitor cardiac devices remotely and predict health conditions.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Neuro Device Group S.A. is a Polish med-tech company, established in 2008 and based in Warsaw, specializing in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's product lineup includes Neuro Device Camri, a diagnostic recording camera for MRI scanners; Neuro Device Scent, which measures neuronal reactions to scents; and Neuro Device Tacti, a stimulator used in preoperative fMRI diagnostics to localize brain sensomotoric areas. In addition to its proprietary devices, Neuro Device Group also distributes a range of high-quality neurological products and medical devices from leading global manufacturers, encompassing areas such as eye tracking, rehabilitation, virtual reality, and fMRI. The company's ongoing mission is to enhance neurological research and improve patient outcomes through innovative technologies.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.

Metys Pharmaceuticals is focused on developing MP-101, a small molecule drug aimed at preventing and treating chemotherapy-induced peripheral neuropathy, a common and distressing side effect of cancer treatments. MP-101 functions as an orally-active modulator of glutamate signaling in the spine and brain, a pathway that has been targeted for new central nervous system therapies. The drug is derived from a patent-pending non-racemic mixture of the enantiomers of dimiracetam, which has demonstrated enhanced pharmacological potency compared to traditional racemic mixtures. Metys Pharmaceuticals has secured exclusive global rights to racemic dimiracetam from Neurotune AG, along with comprehensive regulatory study data to support future clinical trials for MP-101. The company aims to leverage this data to advance its innovative approach in addressing neuropathic pain and other central nervous system disorders.

Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing innovative treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing several drug candidates, including SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers, and SCO-201, which is in late pre-clinical development for solid tumors. Scandion Oncology aims to improve the outcomes and quality of life for cancer patients facing the challenge of drug resistance, a significant obstacle in oncology that affects approximately half of all patients undergoing chemotherapy. The company has established collaboration agreements with the University of Copenhagen to co-develop SCO-301, a candidate designed to counteract drug resistance, and is also exploring the potential of combining SCO-101 with Alligators mitazalimab to enhance anti-tumor effects in resistant tumor models.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Toleranzia is a Swedish biotechnology company developing drugs that harness the immune system's power to treat rare autoimmune diseases. Its pipeline includes TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, both targeting disease-specific proteins.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

ConquerX is a biotechnology company focused on advancing precision medicine through innovative molecular profiling solutions for clinical trials. The company's flagship product, EbeGen, is an electro-chemical biosensor designed to detect multiple molecular targets, including DNAs, RNAs, and microRNAs, simultaneously without the need for sequencing or quantitative PCR, thus offering a cost-effective alternative to existing technologies. Additionally, ConquerX has developed a pan-cancer test that differentiates cancerous cells from healthy ones, utilizing high-throughput genomic and proteomic profiling alongside proprietary nanotechnology. This tool enables oncologists to effectively screen for commonly known biomarkers across various cancer types, thereby enhancing the cancer diagnosis process.

Clover Bioanalytical is a bioinformatics company focused on developing software solutions for bioanalytical chemistry and clinical diagnostics, particularly utilizing mass spectrometry. Established by a team of Ph.D. graduates with extensive experience in both research and business, the company excels in providing advanced data processing capabilities and statistical analysis in the biomedical field. Clover's expertise encompasses mass spectrometry applications, medical image processing, and both univariate and multivariate statistical analyses, making it adaptable to a variety of needs within the healthcare sector. The company emphasizes a customer-oriented approach, tailoring its systems to meet client goals and ensuring scalability. Furthermore, Clover aims to address significant scientific challenges in collaboration with hospitals, research centers, and biotechnology firms, employing artificial intelligence to aid in the rapid identification of microorganisms and enhance diagnostic processes.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Founded in Sweden in 2011, Brain Stimulation specializes in innovative neurological rehabilitation. They leverage brain plasticity research to develop effective, individualized care for stroke, dementia, traumatic brain injuries, and other degenerative brain diseases.

Inflection Biosciences Ltd. is a drug development company based in Dublin, Ireland, specializing in the discovery and development of small molecule therapeutics aimed at treating cancer. Founded in 2012, the company focuses on identifying promising early-stage cancer research from academic institutions and other organizations worldwide. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors, which are currently in preclinical development. Inflection Biosciences is committed to advancing these programs through preclinical and early clinical stages, with the intention of partnering with larger pharmaceutical companies for subsequent development and commercialization. The leadership team, comprising individuals with over 60 years of industry experience, leverages a global network of potential partners and service providers to enhance its research and development efforts.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

ImmuneBiotech AB, established in Lund, Sweden in 2013, specializes in the research and development of novel microbiome therapeutics. The company focuses on probiotic lactic acid bacteria and synbiotic formulations that target the gut microbiota and the immune system, aiming to prevent and treat autoimmune and chronic inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

Bioithas is a medical research company focused on developing natural treatments aimed at improving health and quality of life. The company dedicates its efforts to conducting rigorous clinical trials to create personalized therapies that address the root causes of health issues rather than merely alleviating symptoms. By directing research toward unique biotechnological advancements, Bioithas seeks to generate valuable projects that contribute to meaningful scientific outcomes, ultimately enhancing the well-being of individuals.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Cyclomics is a Dutch startup dedicated to transforming cancer care by facilitating faster and more reliable diagnoses, particularly for cancer recurrence. It achieves this through its proprietary circulating tumor DNA (ctDNA) detection technology, CyclomicsSeq. Initially focused on head and neck cancers, the company aims to disrupt cancer diagnostics markets and clinical practices with its innovative solution.

Elypta develops a liquid biopsy platform using metabolism-based biomarkers and artificial intelligence. Its platform measures glycosaminoglycan metabolites in blood and urine, aiming to enable earlier detection and monitoring of various cancer types.

FGen GmbH is a Swiss company founded in 2011 as a spin-off from ETH Zurich, based in Basel. It specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries, facilitating the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in biotech, life sciences, and pharmaceuticals to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on optimizing microbial strains for biotechnological applications by integrating proprietary screening technology with biological engineering tools. This enables clients to achieve efficient and cost-competitive bioproduction of chemicals and proteins.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

TargImmune Therapeutics is a Swiss biotech company specializing in targeted onco-immunotherapy drug development. Its core technology, CTPIC, employs a non-viral vector to target and destroy cancer cells expressing specific receptors while stimulating an immune response.

Mecwins develops nanotechnological platforms for sensitive immunoassays, focusing on applications in oncology, cardiovascular disease, and infectious diseases. Their technology improves healthcare outcomes for at-risk populations.

Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This innovative compound is being investigated as a treatment for type 2 diabetes, obesity, and the rare painful condition known as erythromelalgia. XEN-D0501 has undergone testing in over 300 subjects during phase 1 and phase 2 trials, demonstrating a favorable safety profile in healthy volunteers and patients with various conditions, including overactive bladder disease and chronic cough. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical studies have completed successfully without any registered side effects, allowing XEN-D0501 to advance to longer clinical trials. In July 2022, Pila Pharma received US Orphan Drug Designation for this compound in the context of erythromelalgia.

Raylytic GmbH is a software development company specializing in automated medical image analysis and clinical data extraction. Founded in 1999 and headquartered in Leipzig, Germany, with additional offices in Magdeburg, Raylytic offers the UNITY platform, which provides a fully integrated solution for clinical trial management and medical data collection. This web-based platform streamlines the setup and execution of clinical data collection tasks, including the management of case report forms and patient-reported outcome measures, while employing advanced algorithms for the precise analysis and quantification of radiological images. Raylytic's services encompass a range of activities, including clinical trials for medical devices, independent qualitative analysis, development of radiographic protocols, quality assurance, data management, and statistical reporting. The company's innovative approach combines industrial and medical image processing with machine learning, enabling efficient and accurate evaluation of medical images for evidence-based medicine and regulatory compliance.

Enzymlogic is a specialized company focused on enzymology and protein science, delivering innovative analytical solutions to the pharmaceutical and biotech sectors. They aim to enhance the drug discovery and development process, ultimately improving patient quality of life through safer and more effective therapeutics. By offering services that help determine kinetic profiles in drug interactions, Enzymlogic provides critical insights into the efficacy and safety of potential medications. Their mission is to support clients in maximizing their return on investment while fostering the development of groundbreaking therapies. Enzymlogic aspires to be a leading reference for organizations engaged in drug discovery through rational analysis approaches.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.

BioMensio develops smart handheld devices for rapid, on-site detection of multiple biological targets. Its core technology enables label-free assays and facilitates development of new bio-screening applications. The company's products include BioMensio devices and a novel miniaturized microarray platform, serving point-of-care, food safety, and bio-security applications.

Animated Language Learning is a multinational developer of software based language solutions serving special needs children across the globe. Their revolutionary approach to paediatric language development is currently undergoing clinical trials in the United States and Europe with ground-breaking results. They are based in Galway City in the west of Ireland with offices in San Francisco, California; Jackson, Mississippi; and Tokyo, Japan. Their first commercial product is planned to launch in Q3 2012.

Mercurna B.V. is a biotechnology company based in Oss, Netherlands, founded in 2017. The company focuses on the synthesis of messenger RNA (mRNA) and the development of therapies aimed at treating chronic kidney diseases. As a startup in the biotech sector, Mercurna is dedicated to delivering innovative precision medicine solutions specifically designed for patients suffering from chronic kidney conditions.

Ahead Therapeutics is a start-up biotech company focused on developing innovative treatments for various autoimmune disorders using its proprietary technology. The company employs a unique approach involving PS-liposomes containing auto-autoantigens, which induce antigen-specific immune tolerance through a biomimetic process. This technology has the potential to address multiple autoimmune diseases, including Type 1 Diabetes, Multiple Sclerosis, and Celiac Disease, and is primarily envisioned as a reverse therapeutic vaccine that aims to provide a permanent cure rather than merely palliative care. Ahead Therapeutics' liposome-based platform offers several advantages, such as long-lasting effects, non-systemic immunosuppression, absence of toxicity, cost-effective production, and compatibility with other therapies. The technology has already demonstrated validation in animal models, and the company is progressing towards preclinical regulatory assessments while expanding its pipeline for additional indications. Given that autoimmune diseases affect 5-10% of the global population and often require chronic treatment, Ahead Therapeutics aims to significantly improve patient quality of life and reduce societal healthcare costs.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

CyTuVax is a clinical stage vaccine company focused on addressing significant medical needs through innovative vaccine solutions. The company collaborates with leading European research institutions to leverage its proprietary adjuvant technology, which enhances the effectiveness of vaccines by inducing robust humoral and cellular immune responses. This technology not only improves the quality of standard vaccines but also reduces the number of required doses. CyTuVax develops both prophylactic vaccines targeting viral and bacterial pathogens and therapeutic vaccines aimed at treating cancer. With a strong emphasis on patient-centered development, the company aims to deliver advanced vaccination strategies that meet critical health challenges.

Gondola Medical Technologies SA is a Swiss company dedicated to the research and development of innovative medical devices aimed at enhancing rehabilitation for individuals with neurological and osteoarticular conditions. Founded in 2011 and headquartered in Stabio, the company has created the GONDOLA medical device, which employs Automated Mechanical Peripheral Stimulation (AMPS) to address motor symptoms associated with Parkinson's disease. This non-invasive device targets issues such as freezing of gait, slowness of movement, and balance difficulties. The GONDOLA device is designed for short-term use, allowing patients to wear it on their feet for a few minutes, and can be utilized in both home environments and clinical settings. Regular use of the device, ideally twice a week, sustains its therapeutic benefits, which can last from three to five days after treatment.

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and personalized treatment of patients.

Biocompatibility Innovation (BCI), established in 2014 in Padua, Italy, specializes in biotechnologies for biomedical applications. The company develops and manufactures highly biocompatible implantable prostheses, both biological and polymeric, using its proprietary FACTA® and PROTEGO technologies. These innovations extend the lifespan of bioprostheses and enhance the biocompatibility of implantable medical devices. BCI also provides third-party testing services and develops new proprietary treatments. Led by experienced researchers and managers in biotech and biomedicine, BCI aims to improve clinical management, patient quality of life, and lower healthcare costs.

RegStem is an early-stage biopharmaceutical company focused on repurposing existing molecules and developing new treatments within the regenerative medicine sector. The company specifically targets rare muscle and blood diseases that present significant unmet medical needs. Its research and development efforts are centered on innovative molecules intended for human therapies, including the repurposing of drugs aimed at reconstituting and repairing bone marrow during acute aplasia and promoting skin healing after scarring. By stimulating and controlling the differentiation of stem cells, RegStem aims to provide effective solutions for patients suffering from chronic skin conditions and other serious health issues.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative drug treatments for neurological disorders, particularly Parkinson's disease. The company has developed several clinical candidates, including Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa trials for dyskinesia, and IRL752, which has also progressed through Phase IIa trials for postural dysfunction. In addition to these, IRLAB is advancing other research initiatives aimed at addressing neurodegenerative conditions and the effects of aging. These include programs designed to develop alternatives to levodopa, a common Parkinson's treatment, and additional compounds targeting various dysfunctions associated with Parkinson's disease. Based in Gothenburg, Sweden, IRLAB is committed to enhancing the quality of life for patients suffering from neurological and psychiatric illnesses through its innovative therapeutic approaches.

Filterlex Medical is a medical device company focused on cardiovascular embolic protection. It develops embolic protection devices to reduce the risk of stroke and other embolic complications during catheter-based structural heart procedures, including transcatheter aortic valve implantation. Its CAPTIS full-body embolic protection device is designed for intuitive deployment and retrieval and is compatible with multiple catheter sizes, enabling integration into existing workflows. The company aims to improve patient safety during minimally invasive heart valve replacement procedures. It was founded in 2015 and is based in Yokneam, Israel.

CorAssist Cardiovascular Ltd. is a clinical stage medical device company based in Haifa, Israel, focused on developing innovative products for treating heart failure with preserved ejection fraction and diastolic dysfunction. The company offers CORolla, an elastic self-expanding device designed to be implanted inside the left ventricle through minimally invasive procedures, including transapical and percutaneous approaches. This device enhances cardiac diastolic function by improving diastolic dynamics and filling performance without the need for an external power source. Additionally, CorAssist's ImCardia is a device that attaches to the external surface of the left ventricle and is implanted through a straightforward off-pump procedure, further contributing to the improvement of diastolic function in heart patients. Founded in 2003, CorAssist aims to address the unmet needs in heart failure treatment through its proprietary technology.

Khondrion is a clinical-stage pharmaceutical company focused on discovering and developing therapies targeting mitochondrial disease. Led by Professor Jan Smeitink, a renowned expert in mitochondrial medicine, the company advances its proprietary science through a wholly-owned pipeline of potential small molecule medicines.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.

Stayble Therapeutics AB, headquartered in Gothenburg, Sweden, is a clinical-stage pharmaceutical company focused on developing a minimally invasive injection treatment for chronic discogenic low back pain. Their lead product candidate, STA363, is an intradiscally injected formulation designed to alleviate or eliminate pain by addressing the root causes of instability and inflammation within the affected discs. Having completed a Phase 1b clinical trial, STA363 targets patients who have not responded to conventional treatments such as analgesics and physiotherapy, offering a potential alternative to surgery. The company's experienced team comprises a renowned back-pain researcher, seasoned bio-entrepreneurs, and former senior pharmaceutical management, aiming to provide relief to millions of people disabled by chronic low back pain.

Dart Diagnostics is a diagnostic company focused on enhancing diagnostic assays to provide better and earlier results in various fields, including clinical diagnostics, water analysis, and food safety. The company specializes in the development of bio-inspired polymers for nanotechnology, which amplify the signal from immunoassays. This innovation enables healthcare professionals to achieve more accurate results efficiently, ultimately saving time, reducing costs, and improving patient outcomes. Founded by scientists who are acutely aware of the challenges in detection, Dart Diagnostics aims to address the widespread need for improved diagnostic solutions across multiple sectors.

Founded in Italy in 2016 by Silvia Scaglione and Maurizio Aiello, React4life is a biotech company dedicated to advancing biomedical research. The company specializes in the development of MIVO®, an innovative organ-on-a-chip technology that enhances the reliability and predictability of various applications such as pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals.

AXO Science develops advanced diagnostic tools that combine forensic and medical applications. Its flagship product is a multi‑parameter testing platform that uses a polymer‑based biochip with grafted oligonucleotide probes to deliver rapid, molecular‑level characterizations. The technology supports forensic laboratories and clinical diagnostics, enabling precise identification of biological markers and improving public health outcomes.

MEDIKURA Digital Health GmbH, founded in 2017 and based in Munich, Germany, specializes in developing a platform focused on drug safety issues and analysis. The company offers a suite of products, including MEDIKURA Capture, which allows users to report side effects online; MEDIKURA Insights, which provides insights into drug safety and customer satisfaction; and MEDIKURA Guide, designed to help users understand the risks and benefits of their medications. Catering primarily to the pharmaceutical and insurance industries, MEDIKURA aims to enhance drug safety and improve the overall understanding of medication-related risks.

Sedicidodici develops medical devices that assess the risk of thrombotic events, such as stroke or heart attack, by measuring platelet activation and fibrin formation in blood samples. Their tools also monitor the effects of anticoagulation and antiplatelet therapies.

BioBlocks is a collaborative medicinal chemistry research organization that specializes in drug discovery, guiding clients from initial lead discovery to identifying development candidates. The company offers a comprehensive drug discovery platform that includes a fragment library and compound database, assisting clients in identifying viable new chemical entities for biological pathways. BioBlocks also provides preclinical development and clinical trial management services, enabling pharmaceutical companies to generate and optimize quality clinical candidates. By fostering collaboration with clients, BioBlocks aims to enhance the effectiveness, speed, and reliability of drug discovery programs, ultimately advancing compounds into clinical trials.

Inpharmatis offers comprehensive regulatory affairs services to Life Science Industry including Drug Development and Vigilance Services to pharmaceutical, medical device, food supplements, cosmetic and biotech companies. Their area of expertise lies in the European & CIS market. A multi-disciplinary team of qualified regulatory affairs consultants is at your disposal for all aspects of your marketing authorisation applications for active substances and human medicinal products. Inpharmatis shall provide full regulatory support over the whole life cycle of your product.

CytaCoat is a private Swedish company based in the Karolinska Institutet Science Park in Solna, Stockholm. Founded by researchers from the Karolinska Institute and the Royal Institute of Technology, the company focuses on developing a proprietary antibacterial coating technology for medical devices. This innovative coating is designed to combat healthcare-associated infections by repelling problematic pathogenic bacteria without the use of antibiotics, thus minimizing the risk of antibiotic resistance. CytaCoat's technology is characterized by its stability under varying pH and ionic conditions, ensuring safety and effectiveness. The company operates a fully equipped laboratory for microbiological evaluation and optimization of its technology, and it has established collaborations with clinical partners such as the Karolinska University Hospital. Additionally, CytaCoat engages with regulatory consultants and clinical research organizations to guide its product development and commercialization efforts.

BioDatup specializes in streamlining clinical trial management using advanced technology. Its platform integrates cutting-edge medical information management with innovative data analysis techniques, enabling real-time monitoring, AI-driven insights, and error reduction for pharmaceutical labs, hospitals, and research centers.

EIO Biomedical is a biotechnology company based in Nazareth, Israel, focused on developing a medical device aimed at preventing post-surgical adhesions. Established in 2016, the company has created a spray containing essential blood clotting proteins that promotes targeted clotting at the wound site. This innovative product alters the formation of the fibrin network by cross-linking fibrin to establish a barrier against cell adhesion. As a result, it enables surgeons to conduct both laparoscopic and open surgeries with reduced concern for significant surgical complications. EIO Biomedical has received financial backing from NGT3 VC and the Israeli Office of Chief Scientist, highlighting its potential impact in the field of surgical procedures.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.

AuriGen Medical Limited is an innovative company based in Dublin, Ireland, specializing in electrophysiology and structural heart solutions. Founded in 2016, AuriGen develops advanced left atrial appendage (LAA) implants aimed at addressing the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). The company targets a significant and growing patient population, particularly those with medication-resistant AF, which affects over three million individuals across the United States and Europe. AuriGen's technology offers a novel trans-septal implant that not only treats AF effectively but also reduces the reliance on anticoagulants and anti-arrhythmic medications. By providing cost-effective treatment options, AuriGen aims to improve patient outcomes while addressing the rising financial burden of managing chronic cardiac conditions in aging populations.

Biomode is a Portuguese startup based in Caldas das Taipas that specializes in the development of rapid and accurate molecular diagnostic tests for identifying pathogens in the food, environmental, and life science sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridisation (PNA-FISH) technology, Biomode's diagnostic kits eliminate the need for DNA extraction or amplification, making them less susceptible to inhibitory compounds and capable of detecting only viable bacterial cells. The company is preparing to launch its first product, Probe4Salmonella®, for the detection of Salmonella in food samples, with plans to follow up with kits for Listeria monocytogenes and E. coli O157:H7. Additionally, Biomode has developed Probe4Pylori®, a kit for the rapid identification of clarithromycin resistance in H. Pylori strains, which is currently seeking investigational device exemption from the FDA to initiate field trials. Founded by a team of researchers from the universities of Minho and Porto, Biomode stands out as one of the few groups globally capable of designing PNA-FISH probes targeting specific pathogens.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

GlyCardial Diagnostics S.L. is a biotechnology company based in Barcelona, Spain, established in 2017 as a spin-off from the Catalan Institute of Cardiovascular Sciences and the Spanish National Research Council. The company specializes in developing point-of-care diagnostic devices aimed at detecting abnormal levels of the Apo J-Glyc protein in blood, serving as a biomarker for the early diagnosis of myocardial ischemia. GlyCardial's innovative technology seeks to identify patients at risk of experiencing ischemic attacks before they occur, addressing significant unmet medical needs in cardiovascular care. By facilitating timely healthcare decisions, the company's solutions aim to reduce the risk of irreversible myocardial damage and heart failure, ultimately improving patient outcomes following ischemic events.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

ViVO Smart Medical Devices specializes in the design and manufacturing of innovative medical devices aimed at enhancing patient care in the healthcare sector. The company holds an exclusive worldwide license for the Pupiloscope, a novel handheld device that facilitates real-time detection, assessment, and monitoring of pupil reactivity in patients with head trauma. In addition to developing proprietary products, ViVO offers a range of services including rapid prototyping, project management, testing, quality control, and full assembly. These services are tailored to support med-tech companies and clients in improving treatment outcomes and advancing healthcare solutions.

SunRegen is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. The company specializes in creating drugs aimed at treating a range of conditions, including neurological, neuromuscular, and ophthalmic disorders. Their initial product candidates are designed to target primary optical atrophy while also being evaluated for use in serious conditions such as ALS, Huntington's disease, Alzheimer's, and Parkinson's disease. SunRegen's approach is centered on delivering drug candidates with neuroprotective properties and promoting neurite outgrowth, which may offer favorable safety and tolerability profiles. The company is driven by a team of experienced professionals who have extensive backgrounds in drug development and clinical research across the pharmaceutical and technology sectors, all committed to delivering transformative treatments to patients in need.

InDex Pharmaceuticals AB, founded in 2016 and based in Stockholm, Sweden, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for immunological diseases. Its flagship product, cobitolimod, is designed to provide local anti-inflammatory effects, healing mucosa and improving clinical symptoms in patients with ulcerative colitis. The company's platform technology involves DNA-based ImmunoModulatory Sequences (DIMS), which are used to treat a variety of immunological diseases. Additionally, InDex Pharmaceuticals offers DiBiCol, a diagnostic kit that monitors biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy.

Z.M.D. Medical develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system. Z.M.D has set a goal to produce probiotic preparations to rehabilitate distressed colon microflora in order to eliminate cancer from patients’ immune systems and help it recover. Probiotic is designed to eliminate cancerous conditions in patients. This project is also based on the onco-lytic activity of bacterial flora of human intestines. When a patient suffers from low onco-lytic activity, the bacteria must be replaced with the same bacteria with high onco-lytic activity taken from a healthy donor. This idea was tested in animal experiments and is currently being prepared for clinical trials.

Avectas is a cell engineering technology company focused on facilitating the manufacture of engineered cell therapies for drug developers. Its platform allows for the ex-vivo modification of various cell types, including T cells for immuno-oncology applications, by permeabilizing cell membranes to enable efficient transfer of advanced molecules such as mRNA, proteins, and gene editing tools. This innovative approach contrasts with traditional vector-free delivery methods, as it maintains high levels of cell viability and functionality while eliminating the need for recovery time. As a result, Avectas' technology streamlines the process of producing potent engineered cell therapies at therapeutic volumes, enhancing efficiency and reducing costs for developers in the cell therapy market.

Glucostratus Ltd is focused on developing and delivering digital solutions for remote blood glucose monitoring, targeting individuals with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company enables patients to share their glucose data with healthcare providers via a cloud platform, allowing for improved management of individual health outcomes. Glucostratus’s solutions include a software-as-a-service (SaaS) platform that facilitates easy access for doctors and nurses to patient results, as well as an Internet of Things (IoT) solution tailored for elderly diabetics who may lack technical skills. This comprehensive approach addresses the growing needs of the home care sector, ensuring that both patients and healthcare professionals can effectively monitor and manage diabetes treatment.

SynAct Pharma AB, based in Lund, Sweden, focuses on developing treatments for acute exacerbations in inflammatory diseases through its subsidiary, SynAct Pharma ApS. The company’s lead drug candidate, AP1189, targets arthritis, including psoriatic arthritis, which affects a significant proportion of psoriasis patients. Preclinical studies indicate that AP1189 possesses a distinctive ability to reduce inflammation while promoting bleeding, potentially mitigating joint damage following acute inflammatory episodes. The drug is designed for convenient once-daily oral administration. SynAct Pharma aims to advance AP1189 through clinical trials, with results from a Phase I study anticipated. Following safety and tolerability evaluations, the company plans to pursue a clinical trial application for patients with active arthritis, and upon successful proof of concept, intends to establish commercial partnerships with major pharmaceutical firms.

FlowForma is a provider of Business Process Management (BPM) tools for Microsoft Office 365®. It empowers users to automate processes such as HR on-boarding, new product development, and clinical trials without coding. Recognized by Microsoft and trusted by over 110,000 users, FlowForma is headquartered in Dublin with offices in London and Boston.

Beactica Therapeutics specializes in precision oncology, focusing on developing novel small molecule therapeutics for genetically defined cancers with significant unmet clinical need. The company employs a molecular interaction-based drug discovery engine to generate innovative treatments, including allosteric modulators and targeted protein degraders (PROTACs). Beactica aims to deliver value to patients and shareholders by advancing its programs into early clinical trials.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

Glycobond is a biotechnology company focused on the development and production of proprietary carbohydrate-binding reagents for diagnostics. The company specializes in creating peptides that detect aberrant and cancer-specific glycosylation, primarily targeting alpha-1 acid glycoprotein (AGP), which is produced mainly in the liver. Glycobond's flagship product, HepaCheC™, is an ELISA-based assay that enables the detection of these specific glycosylation patterns through simple blood sample analysis. Utilizing a patented fucose-binding protein known as Mono-F, this assay has demonstrated promising results in monitoring patients at risk of developing hepatocellular carcinoma (HCC) through longitudinal serum sample analyses. Glycobond's innovations aim to enhance the diagnosis and monitoring of liver diseases and cancer, providing valuable tools for healthcare professionals.

Genomic Expression is a cancer diagnostics company that uses RNA sequencing to help doctors identify the best drug for patients. Its RNA diagnostic platform analyzes real clinical tissue and liquid biopsy samples to detect disease, monitor health, and guide personalized treatment decisions, enabling targeted therapy options based on a patient's RNA profile. Founded in 2009 and based in Beverly, Massachusetts.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

GeneFirst specializes in molecular diagnostics, focusing on infectious diseases, cancer diagnostics, and personalized medicine. It offers sensitive, affordable, and user-friendly diagnostic technologies and products to researchers, clinicians, and pharmaceutical companies, enabling accurate disease detection and safe, effective treatments.

Thomas Medical, Inc. is a manufacturer of medical devices and accessories specifically designed for women's health. Established in 2004 and headquartered in Indianapolis, Indiana, the company produces a range of single-use products, including catheters, procedure trays, uterine manipulators, injectors, endometrial samplers, intrauterine insemination catheters, and electrodes. These products are utilized in various healthcare settings, such as hospitals, surgery centers, radiology/imaging centers, fertility clinics, and OB/GYN practices worldwide. As a subsidiary of MedGyn Products Inc. since September 2020, Thomas Medical is committed to providing high-quality instruments at competitive prices, catering to the diverse needs of professionals in the gynecology and fertility markets.

Ikan Biotech SL is a biotechnology company based in Noáin, Spain, that specializes in developing enzybiotics and preclinical services utilizing zebrafish models. Incorporated in 2015, Ikan Biotech is recognized as the first contract research organization focused on this innovative approach. The company employs zebrafish to create tumor models for testing the efficacy of potential cancer treatments, allowing for the microinjection of tumor cells to streamline drug development. This platform enables the healthcare industry to assess drug candidates' safety and effectiveness at early stages, facilitating research across various sectors, including pharmaceuticals, biotechnology, and agrochemicals.

Verigraft is a biotechnology company specializing in the generation of personalized tissue-engineered transplants for regenerative medicine. Its unique technology platform transforms donated allogeneic tissue into autologous-like tissue, eliminating transplant rejection and the need for lifelong immunosuppression.

Mcule is an online drug discovery platform for pharmaceutical and biotech research. It offers a user-friendly web interface that integrates the core steps of drug discovery, including molecular modeling and compound delivery for hit identification and lead optimization. The platform provides access to a purchasable database of small-molecule compounds and modeling tools that enable researchers to virtually screen millions of candidates and then order selected compounds for experimental testing, supporting early-phase drug discovery projects for virtual pharma teams.

Biomeb is a biotechnology company that provide personalized medicine for prevention, diagnosis and treatment of different pathologies. The company is a spin-off of the University of Lleida, whose mission is to provide personalized medicine, providing new products and services to society. Since its creation, BIOMEB has been dedicated to developing the proof of concepts and clinical studies necessaries to bring their first products: Well B®, Fit B® and FIBRACEP® to the market.

Into.care is a developer of a mobile healthcare collaboration platform that empowers medical staff to enhance their daily routines and improve patient care. The platform integrates patient records, telemetric data, and a smart decision support system, fostering seamless collaboration among healthcare providers. By collecting and transmitting data from connected healthcare devices to secure servers, Into.care aims to streamline operations and reduce administrative burdens faced by caretakers and medical personnel. The platform supports essential functions such as patient administration, work planning, medication management, and management reporting, ultimately aiming to elevate the quality of life for patients and enhance operational efficiency across healthcare organizations.

Amadix develops cancer diagnostics with a focus on non-invasive screening and early detection. It aims to detect tumors years before symptoms and provide screening signatures in blood to address unmet needs in oncology. Its most advanced product, Colofast, is a blood-based signature for colorectal cancer and advanced adenoma screening, designed to reduce mortality from colon cancer by enabling early intervention. The company pursues analytical validation and demonstration of clinical validity and utility through international multicentre studies, with plans for worldwide commercialization. The leadership combines experience in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property, and independent board members provide guidance on strategy, commercialization, and business development in Europe and the US.

BrachyDOSE is a medical technology company specializing in a quality control tool for cancer radiotherapy treatment. Their innovative solution combines a flexible, disposable radiation dose measurement sensor with deep learning algorithms to provide accurate, real-time data. This empowers oncologists to minimize side effects, optimize treatment efficacy, and enhance patient recovery, potentially reducing overall treatment costs by 3-5 times. The solution consists of a radiation dose measurement sensor, a data retrieval scanner, and an injury prediction algorithm for decision support. BrachyDOSE aims to improve patient outcomes and streamline treatment processes in over 2000 hospitals worldwide.

CORNEA_project is a company dedicated to the research, development and commercialization of solutions and treatments to corneal eye diseases. The cornea is the first surface of the eye, with the highest dioptric power of the ocular optical system, and is of vital importance to see good quality images. Small variations in the corneal surface produces large changes in the quality of patients' vision. Their goal is to ensure the corneal integrity, develop and deliver the best possible treatments for the researched pathologies, and improve the quality of life of patients.

Eversens is a company focused on the design, development, and manufacturing of non-invasive clinical diagnosis systems that detect exhaled biomarkers. By harnessing this technology, Eversens aims to enhance the diagnosis and monitoring of various diseases, ultimately improving the quality of life for patients. The company's commitment to health and welfare is reflected in its mission to provide reliable and accurate diagnostic equipment that offers non-invasive and painless options for patients. Through its innovative approach, Eversens seeks to contribute to a sustainable health system, making significant strides in the field of clinical diagnostics.

Regulaxis is focused in research, development and licensing of human innovative synthetic molecules for high unmet medical needs

Founded in Barcelona, Spain in 2014, Adan Medical Innovation develops innovative medical devices focused on improving the management of anaphylaxis. Their flagship product, AnAPPhylaxis, is a smart case for epinephrine auto-injectors connected to a mobile app, providing users with real-time condition monitoring and reminders, while also offering clear action plans in emergency situations.